Prostate Specific Antigen: Why a 'Normal' PSA Can Be Misleading

What PSA Actually Measures

Prostate specific antigen is a protein produced by both normal and cancerous prostate cells. A blood test measures how much of it is circulating. The higher the level, the greater the statistical chance of cancer, but the relationship is a sliding scale, not a binary.

There's no PSA value that cleanly separates men with cancer from men without it. Among men with a PSA below 0.5 ng/mL, about 6.6% still had cancer. At 2.1 to 3.0 ng/mL, still well under the old "normal" threshold, nearly 24% did. The proportion of aggressive cancers (Gleason score 7 or higher) also climbed with PSA, from 12.5% of cancers at the lowest PSA levels to 25% at the upper end of the "normal" range.

Cancer isn't even the most common reason PSA goes up. A study comparing 148 men with PSA above 4.0 ng/mL and negative biopsies to 64 controls with lower PSA found that prostate volume accounted for 23% of the variation in PSA levels, while inflammation explained another 7%. Benign prostatic hyperplasia, the non-cancerous prostate enlargement that affects most men as they age, is the most frequent cause of a high reading.

Two Trials, Two Answers

The confusion around PSA screening traces back to two landmark studies that launched in the 1990s and reported their first results on the same day in 2009.

The European Randomized Study of Screening for Prostate Cancer (ERSPC) randomized over 182,000 men across eight European countries. After 9 years, screening reduced prostate cancer deaths by 20%. That benefit grew with time: at 13 years, the absolute mortality difference widened, and by 16 years the reduction held at 20%, with fewer men needing to be screened and diagnosed to prevent one death.

The American PLCO trial told a different story, at least on the surface. It randomized about 77,000 men to annual screening or "usual care" and found no mortality difference after 7 to 10 years. Extended follow-up to 15 years confirmed the null result.

So does screening work or not? The answer lies in the control group. In the PLCO trial, PSA testing was already widespread in the United States. An estimated 86% of men in the "usual care" arm got PSA tests on their own during the trial.

The study wasn't really comparing screening to no screening. It was comparing organized screening to opportunistic screening, and those turned out to look similar.

The Göteborg trial, a Swedish arm of the ERSPC that enrolled 20,000 men, had cleaner separation between groups. After 18 years, organized biennial screening reduced prostate cancer mortality by 42%, with a number needed to invite of 139. Opportunistic testing in the control group, by contrast, showed only a 12% mortality reduction and required almost twice as many diagnoses per life saved.

The Overdiagnosis Problem

Screening catches cancers that would never have caused symptoms or death. This is the central trade-off, and the numbers are substantial.

Estimates from the ERSPC suggest that 20% to 50% of screen-detected prostate cancers represent overdiagnosis. A meta-analysis of five trials enrolling over 720,000 men confirmed that screening increases prostate cancer diagnoses without a clear effect on overall mortality. The UK's CAP trial, which offered a single PSA screen to over 400,000 men, found 19% more cancers in the screened group but no difference in prostate cancer deaths after 10 years.

The harms aren't just psychological. Among men screened in the ERSPC, about 18% received false-positive results. Complications requiring hospitalization occurred in 0.5% to 1.6% of men who went on to biopsy. And treatment for screen-detected cancers carries real costs: roughly 1 in 5 men who undergo radical prostatectomy develop long-term urinary incontinence, and about 2 in 3 experience lasting erectile dysfunction.

A modeling study based on ERSPC data calculated that annual screening of men aged 55 to 69 could prevent 9 prostate cancer deaths per 1,000 men over a lifetime, but the quality-adjusted life-years gained were 23% lower than the raw life-years gained, eaten away by the long-term effects of overdiagnosis and treatment.

Who Should Consider a PSA Test

The US Preventive Services Task Force updated its stance in 2018. For men aged 55 to 69, the decision to screen should be individual, based on a conversation about benefits and harms. For men 70 and older, the Task Force recommends against screening because the harms outweigh the potential benefits at that age.

The European Association of Urology takes a somewhat more proactive position, recommending PSA testing as part of a risk-adapted detection strategy. Rather than blanket screening or blanket avoidance, they advocate using baseline PSA to determine screening intervals, with additional tools like risk calculators and MRI to decide who actually needs a biopsy.

Several factors tilt the risk-benefit balance. African American men have higher prostate cancer incidence and mortality. Men with a first-degree relative who had prostate cancer face increased risk. For these groups, earlier and more attentive screening makes more sense.

On the other end, men with limited life expectancy are unlikely to benefit, since those with longer life expectancy stand to gain the most from early detection.

A baseline PSA in your 50s can itself be informative. Men with very low PSA levels at baseline have a low risk of future aggressive cancer, and can be screened less often. Those with higher baseline values can be followed more closely. Instalab's Total PSA test ($19) gives you that baseline number without a referral, which can anchor the screening conversation with your doctor.

MRI Is Changing the Equation

Much of the harm from PSA screening comes from what happens after an elevated result: systematic biopsies that sample tissue randomly across the prostate, catching slow-growing cancers that didn't need to be found.

The GÖTEBORG-2 trial tested a different approach. Among nearly 38,000 men aged 50 to 60, those with elevated PSA got an MRI first. One group underwent MRI-targeted biopsy only, while a reference group got both targeted and systematic biopsies. The MRI-only approach cut overdiagnosis of clinically insignificant cancer in half (0.6% vs. 1.2%) while detecting nearly the same rate of significant cancers.

The cancers that MRI-only screening missed were all intermediate-risk, low-volume tumors managed with active surveillance rather than immediate treatment. This suggests that adding MRI to the screening pathway preserves the cancer-detection benefit of PSA testing while dramatically reducing the overdiagnosis that has made screening so controversial.

What a PSA Result Means for You

A PSA test is not a cancer test. It's a risk-stratification tool. A low result is reassuring but not a guarantee. A high result is usually caused by something other than cancer, most often a large or inflamed prostate.

The research supports screening for men aged 55 to 69 who want to reduce their chance of dying from prostate cancer, provided they understand the trade-offs. The benefit is real: the ERSPC showed a 20% relative mortality reduction that held steady over 16 years of follow-up, with the absolute benefit widening over time. But so is the risk of finding a cancer that never would have mattered, and facing treatment decisions with lasting side effects.

The clearest path forward is the one the evidence increasingly supports: use PSA as a first filter, follow elevated results with MRI rather than immediate biopsy, and reserve treatment for cancers that genuinely need it. That approach captures the mortality benefit of screening while sidestepping much of the harm that gave PSA testing a bad name.